Takeda Pharmaceutical Future Growth

Future criteria checks 3/6

Takeda Pharmaceutical is forecast to grow earnings and revenue by 23.6% and 1% per annum respectively. EPS is expected to grow by 23% per annum. Return on equity is forecast to be 4.2% in 3 years.

Key information

23.6%

Earnings growth rate

23.0%

EPS growth rate

Pharmaceuticals earnings growth	14.0%
Revenue growth rate	1.0%
Future return on equity	4.2%
Analyst coverage	Good
Last updated	02 Aug 2024

Recent future growth updates

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Jun 30

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

May 12

Recent updates

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 02

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Jul 25

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Jul 11

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Jun 30

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Jun 11

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

May 21

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

May 12

Earnings and Revenue Growth Forecasts

TSE:4502 - Analysts future estimates and past financials data (JPY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	4,495,559	280,290	681,540	1,027,655	16
3/31/2026	4,425,565	204,659	678,080	1,004,552	17
3/31/2025	4,399,837	78,547	683,055	945,262	16
6/30/2024	4,413,134	149,920	444,957	794,248	N/A
3/31/2024	4,263,762	144,067	235,614	716,344	N/A
12/31/2023	4,169,049	178,219	-129,035	731,449	N/A
9/30/2023	4,154,414	191,626	129,243	963,227	N/A
6/30/2023	4,113,631	301,398	180,765	985,315	N/A
3/31/2023	4,027,478	317,017	343,467	977,156	N/A
12/31/2022	3,944,611	274,525	817,615	1,059,047	N/A
9/30/2022	3,749,354	213,167	789,089	1,028,328	N/A
6/30/2022	3,591,868	197,389	798,367	1,040,488	N/A
3/31/2022	3,569,006	230,059	937,068	1,123,105	N/A
12/31/2021	3,465,991	438,515	902,309	1,148,481	N/A
9/30/2021	3,401,450	473,105	777,572	1,018,931	N/A
6/30/2021	3,345,565	431,178	793,645	1,031,928	N/A
3/31/2021	3,197,812	376,005	774,463	1,010,931	N/A
12/31/2020	3,199,240	180,631	608,015	795,408	N/A
9/30/2020	3,221,804	56,051	498,511	720,676	N/A
6/30/2020	3,243,917	119,743	479,618	694,824	N/A
3/31/2020	3,291,188	44,241	452,042	669,752	N/A
12/31/2019	3,236,697	13,275	402,421	601,798	N/A
9/30/2019	2,876,782	83,262	399,600	551,732	N/A
6/30/2019	2,496,511	63,959	266,965	408,797	N/A
3/31/2019	2,097,224	135,192	194,365	328,479	N/A
12/31/2018	1,780,976	110,414	221,992	336,742	N/A
9/30/2018	1,769,726	140,738	225,190	328,658	N/A
6/30/2018	1,772,125	120,339	207,862	343,761	N/A
3/31/2018	1,770,531	186,886	N/A	377,854	N/A
12/31/2017	1,785,773	190,172	N/A	376,566	N/A
9/30/2017	1,762,667	163,457	N/A	316,619	N/A
6/30/2017	1,746,286	160,202	N/A	285,157	N/A
3/31/2017	1,732,051	114,940	N/A	261,363	N/A
12/31/2016	1,729,967	132,194	N/A	-8,176	N/A
9/30/2016	1,754,130	150,081	N/A	42,293	N/A
6/30/2016	1,795,088	155,110	N/A	57,618	N/A
3/31/2016	1,807,378	80,166	N/A	25,491	N/A
12/31/2015	1,831,096	-111,874	N/A	203,553	N/A
9/30/2015	1,830,521	-152,827	N/A	192,836	N/A
6/30/2015	1,812,971	-154,591	N/A	189,123	N/A
3/31/2015	1,777,824	-145,775	N/A	182,517	N/A
12/31/2014	1,744,795	75,405	N/A	N/A	N/A
9/30/2014	1,714,694	103,390	N/A	240,094	N/A
6/30/2014	1,692,531	110,981	N/A	N/A	N/A
3/31/2014	1,691,685	106,658	N/A	148,335	N/A
12/31/2013	1,655,033	103,330	N/A	N/A	N/A
9/30/2013	1,598,674	76,159	N/A	120,224	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4502's forecast earnings growth (23.6% per year) is above the savings rate (0.3%).

Earnings vs Market: 4502's earnings (23.6% per year) are forecast to grow faster than the JP market (8.9% per year).

High Growth Earnings: 4502's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4502's revenue (1% per year) is forecast to grow slower than the JP market (4.1% per year).

High Growth Revenue: 4502's revenue (1% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4502's Return on Equity is forecast to be low in 3 years time (4.2%).

Takeda Pharmaceutical Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Consensus EPS estimates fall by 17%

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Consensus EPS estimates fall by 18%

Consensus EPS estimates fall by 11%

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

Recent updates

Earnings Beat: Takeda Pharmaceutical Company Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical (TSE:4502) Is Increasing Its Dividend To ¥98.00

Consensus EPS estimates fall by 17%

Takeda Pharmaceutical's (TSE:4502) Upcoming Dividend Will Be Larger Than Last Year's

Final dividend of JP¥98.00 announced

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited (TSE:4502) Yearly Results: Here's What Analysts Are Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Consensus EPS estimates fall by 18%

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda Pharmaceutical (TSE:4502) Takes On Some Risk With Its Use Of Debt

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Consensus EPS estimates fall by 11%

Some Investors May Be Willing To Look Past Takeda Pharmaceutical's (TSE:4502) Soft Earnings

Takeda Pharmaceutical Company Limited Just Recorded A 6.0% EPS Beat: Here's What Analysts Are Forecasting Next

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical (TSE:4502) Is Due To Pay A Dividend Of ¥94.00

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Upcoming dividend of JP¥94.00 per share

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Pharmaceutical (TSE:4502) Has Announced A Dividend Of ¥94.00

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical (TSE:4502) Will Pay A Dividend Of ¥94.00

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Consensus EPS estimates increase by 13%

Consensus EPS estimates fall by 24%

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Upcoming dividend of JP¥94.00 per share at 4.0% yield

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

New minor risk - Earnings quality

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Consensus EPS estimates fall by 19%

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet